These products are often referred to as compounded GLP-1 medications. SAHPRAs enforcement action On 23 May 2026, SAHPRA announced that it had intensified enforcement action against the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines containing semaglutide, tirzepatide, or combination formulations
Track Your Progress and Make Adjustments Tracking your meals, exercise, and symptoms such as hot flashes, GI disturbances, or energy levels can help you to understand how your nutrition and medications are impacting you during menopause
Keep at least 48 hours between doses
Clinician-guided protocol options
Similarly, men with severe kidney disease, active pancreatitis, or diabetic retinopathy require careful medical evaluation before starting semaglutide
The difference is FDA approval and resulting insurance/pricing implications